Gender | Invasive carcinoma of breast | Core needle biopsy | Excision biopsy | TNM clinical staging
Item
women with a recent diagnosis of t1 or t2 non-invasive breast cancer by large core needle or excisional biopsy
boolean
C0079399 (UMLS CUI [1])
C0853879 (UMLS CUI [2])
C1318309 (UMLS CUI [3])
C0184921 (UMLS CUI [4])
C3258246 (UMLS CUI [5])
tissue analysis Acceptable | Breast tissue sample; Sufficient; Evaluation Research
Item
confirmation that tissue was processed in methods acceptable to protocol and sufficient tissue remains post-diagnostic analyses to perform research assessments
boolean
C3161513 (UMLS CUI [1,1])
C1879533 (UMLS CUI [1,2])
C0444070 (UMLS CUI [2,1])
C0205410 (UMLS CUI [2,2])
C0015195 (UMLS CUI [2,3])
Reexcision Planned
Item
reexcision planned within 10 days to 6 weeks from study start
boolean
C0184913 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
Tamoxifen | Raloxifene | Administration Duration
Item
if on prevention tamoxifen or raloxifene, must have begun administration at least six weeks prior to initial biopsy and continue through reexcision
boolean
C0039286 (UMLS CUI [1])
C0244404 (UMLS CUI [2])
C1533734 (UMLS CUI [3,1])
C0449238 (UMLS CUI [3,2])
Hormone replacement therapy Before Biopsy
Item
no hormone replacement therapy within the 90 days prior to biopsy
boolean
C0282402 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C0005558 (UMLS CUI [1,3])
Tamoxifen | Raloxifene | Administration Duration
Item
if on prevention tamoxifen or raloxifene, must have begun administration at least six weeks prior to initial biopsy and continue through reexcision
boolean
C0039286 (UMLS CUI [1])
C0244404 (UMLS CUI [2])
C1533734 (UMLS CUI [3,1])
C0449238 (UMLS CUI [3,2])
Metastatic Neoplasm Evidence of
Item
no evidence of metastatic malignancy of any kind
boolean
C2939420 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
Asthma | Hypersensitivity Aspirin | Anti-Inflammatory Agents, Non-Steroidal | celecoxib | Cyclooxygenase 2 Inhibitors | Condition Non-Malignant chronic | Low Dose ASA
Item
no history of asthma, allergy asa, nsaids, celecoxib or other cox-2 inhibitors for a chronic non-oncological condition with the excision of low dose asa (160 mg daily) during 4 weeks prior to biopsy and for the duration of the study.
boolean
C0004096 (UMLS CUI [1])
C0020517 (UMLS CUI [2,1])
C0004057 (UMLS CUI [2,2])
C0003211 (UMLS CUI [3])
C0538927 (UMLS CUI [4])
C1257954 (UMLS CUI [5])
C0348080 (UMLS CUI [6,1])
C1518371 (UMLS CUI [6,2])
C0205191 (UMLS CUI [6,3])
C0721444 (UMLS CUI [7])
celecoxib Use of | rofecoxib Use of
Item
no celecoxib or rofecoxib use within one month of biopsy
boolean
C0538927 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
C0762662 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
Gastrointestinal ulcer Requirement Therapeutic procedure | Ulcerative Colitis Requirement Therapeutic procedure
Item
no history of gastrointestinal ulcer or ulcerative colitis requiring treatment
boolean
C0237938 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0009324 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
Anticoagulants
Item
no current anticoagulants
boolean
C0003280 (UMLS CUI [1])
Antihormone Therapy Neoadjuvant | Chemotherapy Neoadjuvant
Item
no neoadjuvant antihormone or chemotherapy as treatment following biopsy prior to study entry or concurrently with participation on study
boolean
C2986607 (UMLS CUI [1,1])
C0600558 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2,1])
C0600558 (UMLS CUI [2,2])
Aromatase Inhibitors
Item
no aromatase inhibitor in the six months prior to participation
boolean
C0593802 (UMLS CUI [1])
Lithium
Item
no concomitant lithium
boolean
C0023870 (UMLS CUI [1])
Blood Coagulation Disorder Significant
Item
no known significant bleeding disorder
boolean
C0005779 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])